ERNA Stock Catalyst: Ernexa Therapeutics Announces Partnership with Cellipont Bioservices to Advance ERNA-101

Oct 28, 2025 · 4:00pm ET

Collaboration aims to move ERNA-101 into clinical trials for ovarian cancer.

Max move

+128.8%

High of day $71.50

Sparker timei

4:00pm ET

ERNA · Oct 28, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Ernexa Therapeutics Inc. (Nasdaq: ERNA) announced a partnership with Cellipont Bioservices to advance its drug candidate ERNA-101 toward clinical trials for the treatment of ovarian cancer. The collaboration leverages Cellipont Bioservices' expertise in drug development and manufacturing to support the progression of ERNA-101.

The partnership will focus on the preclinical and clinical development phases of ERNA-101, with the goal of initiating clinical trials in the near future. Ernexa Therapeutics will utilize Cellipont Bioservices' advanced technology platforms to optimize the drug candidate and prepare for regulatory submissions.

Ernexa Therapeutics currently has a free float of 3,335,400 shares and 7,848,900 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ERNA sparks.

Download Sniper App →

Catch the next ERNA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →